Efficient immunotherapies such as anti-CD20 monoclonal antibody (rituximab) and antibodies against CD79b (polatuzumab) have already been approved for DLBCL (Roth et al., 2021). This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.